CYTOTOXICTISALANS

Salan Ti(IV) Complexes as Novel Anti-Cancer Chemotherapeutics

Coordinatore	THE HEBREW UNIVERSITY OF JERUSALEM.    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Israel [IL]
Totale costo	167˙774 €
EC contributo	149˙598 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2011-PoC
Funding Scheme	CSA-SA(POC)
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-03-01   -   2013-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE HEBREW UNIVERSITY OF JERUSALEM.  Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Ms. Nome: Jane Cognome: Turner Email: send email Telefono: +972 2 6586676 Fax: +972 7 22447007	IL (JERUSALEM)	hostInstitution	149˙598.84

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cisplatin is a platinum-based complex used widely as a chemotherapeutic drug. However, due to its limitations, including narrow activity range and severe side effects, other transition metal complexes are investigated as antitumorur agents. Titanium complexes that previously reached clinical trials showed fair activity, and were mainly limited by rapid decomposition in water, within minutes. Titanium complexes of diamino bis(phenolato) ('salan') ligands studied in our laboratory under the ERC grant demonstrate extremely high stability for up to weeks in water solutions. Importantly, they have shown great potency as anti-tumour agents towards a number of cells in vitro. Their activity exceeds that of cisplatin by up to two orders of magnitude. In particular, halogenated compounds at specific positions demonstrate a combination of exceptional hydrolytic stability and particularly high cytotoxicity, and are covered in a patent application. In addition, minor effect on regular cells was observed. As the titanium has been previously shown based on in vivo testing to be significantly less toxic than platinum, (and is commonly found in food and cosmetics), several pharmaceutical companies expressed interest in our compounds. However, in vivo activity and some mechanistic insights (required for FDA approval) are fundamental for allowing commercialization. Therefore, we propose to conduct a series of experiments that will bring this research to a more 'mature' level suitable to be undertaken by pharmaceutical companies. These include in vivo testing on mice to establish safety and activity towards different cells and by different administration techniques, including IV. Additionally, as solubility is an issue, different formulations will be assessed. Basic mechanistic studies will include evaluating potential interaction with DNA. All these studies are not covered by the ERC grant, and will be conducted in collaboration with a biologist expert in cancer research.'